8-K: Assembly Bio adopts 2026 bonus plan; CEO target up

Assembly Biosciences approved a 2026 cash bonus plan and raised CEO Jason Okazaki’s target bonus to 65% of base salary.

Summary

• Approved the 2026 Corporate Bonus Plan effective January 1, 2026, covering cash incentive payouts based on corporate and individual goals over the January 1–December 31 performance period.
• Corporate vs. individual weighting by level: CEO 100% corporate; C-level/SVP/VP 75% corporate/25% individual; Executive Director/Senior Director/Director 50%/50%; Associate Director and below 25%/75%.
• Bonus targets: CEO up to 75% of base salary; other executives 30%–55%; non-executives up to 28%; actual payouts can range from 0x to 1.5x the target.
• Corporate objectives will be set by the Board within 90 days of the period start and may be re-weighted or modified for unanticipated events; the Committee may credit unanticipated accomplishments.
• Payouts are expected in the first quarter following the performance period, no later than March 15; participants must be employed on the payment date to receive any bonus.
• Potential mid-year advanced payments may be authorized if one or more corporate objectives are met by June 30 of the performance period.
• On March 24, 2026, the Compensation Committee increased CEO and President Jason A. Okazaki’s target bonus from 60% to 65% of base salary for fiscal year 2026 via Amendment No. 1.
• The plan is unfunded, subject to the company’s business and financial condition, and bonuses are subject to any company clawback policy and Section 409A considerations.
• Exhibits filed: 10.1 (2026 Corporate Bonus Plan) and 10.2 (Amendment No. 1 to CEO employment agreement).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a modestly positive governance update that clarifies 2026 incentives and slightly increases the CEO’s cash-at-risk, with limited direct financial impact disclosed.

Positives

• Clear, tiered incentive structure aligns payouts with corporate and individual performance (0x–1.5x payout curve).
• CEO bonus target set at 65% of base salary, aligning leadership incentives with 2026 results.
• Governance safeguards include Board/Committee oversight, clawback applicability, and Section 409A alignment.
• Flexibility to recognize unanticipated accomplishments can reward outperformance.
• Option for mid-year advanced bonus payments (if objectives met by June 30) can support retention and morale.

Negatives

• Potential increase in cash compensation expense due to higher CEO target bonus (from 60% to 65%).
• Significant discretion for the Board/Committee to adjust objectives and weightings may reduce pay-for-performance transparency.
• Bonuses are contingent on employment through the payment date, which may be viewed negatively by some employees.
• Plan is unfunded and subject to the company’s financial condition, creating uncertainty around payouts in weaker periods.

Risks

• Any and all bonus payments are subject to the business and financial condition of the company, which may limit or preclude payouts.
• The Board and Committee may adjust corporate objectives and weightings at any time based on unanticipated events, adding outcome uncertainty.
• Participants must remain employed through the payment date to receive bonuses; termination before payment results in forfeiture.
• Bonuses are subject to clawback under company policy or applicable law, creating potential for repayment after distribution.
• The plan is unfunded; participants are general unsecured creditors with no segregated assets to support bonus obligations.

Future Outlook

The Board will finalize corporate objectives within 90 days of the performance period start, with payouts expected in the first quarter following the period (no later than March 15). The Committee retains discretion to adjust weightings/objectives for unanticipated events and may authorize mid-year advanced payments if objectives are met by June 30.

Management Comments

• The Compensation Committee approved the 2026 Corporate Bonus Plan effective January 1, 2026 to motivate, retain, attract and reward employees via performance-based cash incentives.
• The Committee increased CEO Jason A. Okazaki’s target annual bonus from 60% to 65% of base salary for fiscal 2026, to be determined under the Plan.
• Amendment No. 1 to the CEO’s employment agreement provides that the annual performance bonus, if earned, will be paid in a single lump sum no later than 75 days after the end of the applicable period.

Industry Context

StockSavvy.ai notes the plan’s structure—corporate/individual weightings, a 0–150% payout curve, clawback compliance, and short-term deferral timing—is consistent with common practices among U.S. public life-sciences companies, where cash STI plans emphasize milestone-driven performance (R&D, regulatory, and financing) and align leadership pay with company-wide outcomes.

Comparison to Industry Standards

• Payout curve (0–150% of target): StockSavvy.ai notes this is standard among U.S. public biotechs for annual cash incentives, supporting differentiation for under/over-achievement.
• Objective weighting: A 100% corporate weighting for the CEO and mixed corporate/individual weightings for other levels align with typical governance practices to focus top leadership on enterprise outcomes.
• Target levels: A 65% CEO target is within the typical small-cap biotech range (approximately 50%–75%), based on common life-science compensation survey practices; executive and non-executive ranges are also in line with market norms.
• Governance and compliance: Inclusion of clawback applicability and Section 409A alignment reflects current U.S. listing standards and tax compliance expectations adopted broadly across peers.
• Payment timing: Paying no later than mid-March (or within 75 days for the CEO per the amendment) is consistent with the short-term deferral exception under Section 409A commonly used by peers.

Corporate Governance

Stakeholder Impact

• Shareholders: Clearer pay-for-performance framework may support alignment with strategic milestones.
• Employees: Expanded, structured bonus plan offers competitive short-term incentives tied to corporate and individual performance.
• Executives: Higher CEO target bonus increases cash-at-risk aligned with enterprise outcomes.
• Creditors: Plan is unfunded and payments depend on the company’s financial condition, limiting fixed obligations.

Next Steps

• Board to approve and weight corporate objectives within 90 days after January 1, 2026.
• Set and communicate individual objectives per role level and plan procedures.
• Evaluate potential for advanced bonus payments if one or more corporate objectives are met by June 30, 2026.
• Determine and pay bonuses in Q1 following the performance period, no later than March 15 (subject to employment on the payment date).

Key Dates

Keywords

Assembly Biosciences, 2026 Corporate Bonus Plan, executive compensation, cash bonus, performance-based pay, Jason A. Okazaki, Compensation Committee, corporate objectives, individual objectives, clawback policy, Section 409A, Nasdaq, biotech incentives, employment agreement amendment